Developing a vaccine for Clostridioides difficile infections
Administrative Core
This study is working on creating vaccines to help protect people from Clostridioides difficile infections, which can cause serious gut problems, and it brings together a team of researchers to make sure they’re all working well together to make progress.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vanderbilt University Medical Center NIH-funded |
| Lab location | 1 site (Nashville, United States) |
| Project ID | NIH-11044214 on NIH RePORTER |
What this research studies
This research focuses on the development of vaccines targeting Clostridioides difficile, a bacterium that causes severe intestinal infections. The project involves coordinating various activities among researchers to enhance collaboration and ensure effective progress towards vaccine development. Regular meetings and feedback sessions will be held to monitor advancements and address challenges. The Administrative Core will also manage compliance with NIH reporting requirements to maintain transparency and accountability.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at risk of Clostridioides difficile infections, particularly those with a history of antibiotic use or underlying health conditions.
Not a fit: Patients who are not at risk for Clostridioides difficile infections or those who have already been vaccinated may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to an effective vaccine that significantly reduces the incidence of Clostridioides difficile infections.
How similar studies have performed: Previous research has shown promise in developing vaccines for Clostridioides difficile, indicating that this approach has potential for success.
Where this research is happening
Nashville, United States
- Vanderbilt University Medical Center — Nashville, United States (Active)
Researchers
- Principal investigator: Lacy, Dana Borden — Vanderbilt University Medical Center
- Study coordinator: Lacy, Dana Borden
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.